Recursion OS Approach Impact Pipeline Partners Investors About Careers Recursion OS Approach Impact Pipeline Partners Investors About Careers Our bold ambition: Decode biology to radically improve lives. From our earliest days, our story was unlikely. We are a company started by two graduate students and a professor, headquartered in Salt Lake City, Utah. Our humble and unlikely beginnings are foundational to what we’ve built today. We were underdogs, and felt that way. Now we are leaders in this space, and we vow to stay hungry and focused on our mission. We are a biotechnology company scaling more like a technology company, and we are just getting started. Key Facts Numbers 2013 FOUNDING YEAR 300+ TEAM MEMBERS Apply › 100K+ SQ. FT. OF SPACE 70 ft CLIMBING WALL IN OFFICE 4 CLINICAL-STAGE PROGRAMS View Pipeline › 37 PROGRAMS IN OUR PIPELINE View Pipeline › Founders Chris Gibson PHD Blake Borgeson PHD Dean Li MD/PHD HQ SLC UT. USA Investors Timeline Early 2013 Co-founder & CEO Chris Gibson uncovers opportunity to apply ML to cell images while doing PhD at University of Utah. November 5, 2013 Recursion is founded. January 1, 2014 Move into the first lab space at 383 S. Colorow (1,081 sq. feet). October 5, 2015 Lead clinical program REC-994 receives FDA Orphan Drug designation. April 25, 2016 Sign research agreement with Sanofi Genzyme. September 2, 2016 Close Series A financing with lead investor Lux Capital. January 19, 2017 Move into a new lab at 630 Komas Dr. (15,000 square feet). September 25, 2017 Close the Series B financing with lead investor DCVC. July 10, 2018 REC-994 is granted an IND to treat Cerebral Cavernous Malformation. October 19, 2018 Move into current headquarters in Downtown SLC (100,000 sq. ft!) October 24, 2018 Launch first Phase 1 study for REC-994. January 4, 2019 Identify and in-license second clinical-stage asset, REC-2282 for Neurofibromatosis type 2. February 12, 2019 Close the Series C financing with new, lead investor Baillie Gifford. May 6, 2019 Release first open-source data; launch RxRX1 machine learning competition on Kaggle. December 23, 2019 Identify and in-license third clinical-stage asset, REC-3599 for GM2 gangliosidosis April 16, 2020 FDA grants pivotal registration trials to commence in a number of assets April 24, 2020 Release second open-source data; launch RxRX19 & RxRx2 on SARS-CoV-2 virus May 14, 2020 Identify and in-license fourth clinical-stage asset, REC-4881 for solid tumors July 28, 2020 Finalize company's first acquisition in Vium, a digital vivarium™ company September 9, 2020 Secure $239 million in over-subscribed Series D, led by new investor Leaps by Bayer September 9, 2020 Collaborate with Bayer in industry-leading partnership for fibrotic diseases Proud founding member of BioHive, the fastest growing life sciences community in the nation Get In Touch 41 S Rio Grande Street Salt Lake City, UT 84101 phone: (385) 269-0203 fax: (801) 821-2872 info@recursion.com Investor Relations Connect LinkedIn Twitter Youtube